Drug Profile
Research programme: suppressor of cytokine signalling molecules - Zenyth Therapeutics
Alternative Names: Suppressor of cytokine signalling molecules research programme - AmradLatest Information Update: 19 Apr 2010
Price :
$50
*
At a glance
- Originator Zenyth Therapeutics
- Class
- Mechanism of Action Suppressor of cytokine signalling protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Growth disorders; Hepatitis C; Multiple sclerosis; Neutropenia; Obesity
Most Recent Events
- 28 Mar 2006 The programme is available for licensing(http://.www.zenyth.com.au)
- 28 Mar 2006 Preclinical trials in Cancer in Australia (unspecified route)
- 28 Mar 2006 Preclinical trials in Multiple sclerosis in Australia (unspecified route)